Navigation Links
Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
Date:1/18/2008

BEIJING and CLAREMONT, Calif., Jan. 18 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) announced that it has held a meeting at the Beijing Guo Lin Hotel focused on building the Company's Distribution Network. Attendees included representatives from local Soil and Fertilizer Stations, Agriculture Bureaus, and provincial large volume agricultural products dealers.

In different sessions the attendees probed into matters related to factors in building a distribution network. Focus was placed on marketing and collaborative selling as well as development of educational programs for farmers. The Chinese agricultural market is both mature and complex; therefore, Kiwa intends to focus mainly on developing markets for its unique and patented products such as those approved by the China Green Food Association. The Company is also focused on building relationships with distributors and farmers in order to increase market share and revenues.

Mr. Song, Marketing and Sales Director of Kiwa noted, "Kiwa has a comprehensive product line, integrated operational management and market development resources. Based upon the existing products and structural advantages, there will be three aspects to the cooperative efforts with local distributors:
-- Collaborating to develop local market awareness of the benefits of

Kiwa's green products;

-- Collaborating to produce, sell and distribute products; and

-- Providing trade and capital resources."

Mr. Wei Li, the Board Chairman and CEO of Kiwa, stated, "Cooperation with distributors will rely on finance, be led by technology and make advanced products the center of attention. Kiwa will bring advanced products, technological and financial advantages into the relationships with local distributor partnerships. We hope to gain 'double-win' and 'multi-win' results through this multidimensional relationship between product distribution, distribution networks and trade export."

ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION

The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company has acquired the rights to manufacture and market AF-01 Anti-viral Aerosol Agent for use in preventing (blocking) bird-flu disease in Chinese and international markets. The Company has excellent relations with government authorities in China and has developed several innovative, high margin products, while continuing to grow through internal and external product development. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC (http://www.sec.gov) or visit the Company's website at http://www.kiwabiotech.com.

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward- looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation

Yvonne Wang

Tel: +1-626-715-5855

Email: kiwabiotech@gmail.com

Robert Schechter

Equity Communications

Tel: +1-212-499-6809

Email: ir4kiwa@hotmail.com


'/>"/>
SOURCE Kiwa Bio-Tech Products Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
2. Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million
3. Align Technology, Inc. Ranked 23rd in Deloittes Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies
4. Kiwa Bio-Tech Ships 2,700 Tons of Bio-feed in One Month
5. Advanced Bio-Technologies Inc Announces Acquisition by HealthEdge Investment Partners, Tampa FL
6. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
7. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
8. Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million
9. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
10. China Biologic Products Gains Financial Support from Shandong Provincial Government on the Improvement of Production Facilities
11. Monsantos R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... for optics and photonics, has announced an agreement establishing Kinokuniya Company Ltd. as ... relationship with SPIE as the exclusive sales representative for the SPIE Digital Library ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... AptaFluor SAH Methyltransferase Assay , an enabling new high throughput screening (HTS) ... that drive cancer and other debilitating diseases. , Chemical modification of gene expression, ...
(Date:8/8/2017)... , ... August 08, 2017 , ... ... growth factors expressed in human cells, today announced the launch of HumanKine® ... of the type I family of interferons that activate Th1-type innate immune responses against ...
(Date:8/8/2017)... ... August 08, 2017 , ... ... cancer research and personalized medicine, today announced the launch of its second generation ... company’s first generation PD-L1 test, enabling highly sensitive and specific profiling and monitoring ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):